Published in Women's Health Weekly, April 14th, 2005
Noven's net revenues for the quarter ended December 31, 2004, were $12.7 million compared to $11.8 million for the quarter ended December 31, 2003. This 8% increase primarily reflected higher contract revenues, partially offset by lower unit sales of menopausal hormone therapy (HT) products.
Research and development expense for the current quarter increased 44% to $2.2 million, primarily due to ongoing development projects and the addition of new personnel. Marketing, general and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.